Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
Pfizer (NY: PFE)
38.29 USD  +0.26 (+0.68%)
Official Closing Price  /  Updated: 7:59 PM EST, Dec 6, 2019  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 12,213,299
Open 38.28
Bid (Size) 38.03 (5)
Ask (Size) 38.41 (3)
Prev. Close 38.03
Today's Range 38.22 - 38.52
52wk Range 33.97 - 44.99
Shares Outstanding 5,849,571,048
Dividend Yield 3.55%
Performance
YTD
-11.47%
-11.47%
1 Month
+1.81%
+1.81%
3 Month
+4.90%
+4.90%
6 Month
-10.79%
-10.79%
1 Year
-14.87%
-14.87%
Top News
More News
Centogene reporting its financial results for the three months and nine months ended September 30, 2019
from GlobeNewswire News Releases
ImCheck Raises $53 Million Series B to Advance Clinical Pipeline of Novel Gamma Delta T-Cell-Focused Antibodies for Cancer and Autoimmune Diseases
from GlobeNewswire News Releases
More News
Read More
ViiV Healthcare submits New Drug Application to the FDA for fostemsavir, an investigational, first-in-class attachment inhibitor for the treatment of HIV in adults with few treatment options available
from Business Wire News Releases
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
from Business Wire News Releases
UPDATE 1-FDA approves Amgen's biosimilar to J&J's rheumatoid arthritis drug
category companyNews
from Reuters: Company News
GSK seeks FDA approval for investigational HIV treatment
category companyNews
from Reuters: Company News
3 Dividend Stocks You Can Safely Hold for Decades
category Market News , PFE , MYL , and 4 more.
from Motley Fool
Why Sorrento Therapeutics Was Right to Reject Takeover Bids With A 245% Premium
category Market News , PFE , MYL , and 3 more.
from Motley Fool
Better Buy: Amgen vs. Pfizer
category AMGN , Market News , PFE
from Motley Fool
3 Top Growth Stocks to Buy in December
category CLVS , EXEL , GSK , and 4 more.
from Motley Fool
CORRECTED-Novartis's $90 mln Swiss factory to help solve cell therapy bottleneck
category companyNews
from Reuters: Company News
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.